Evidens för prednisolon i lågdos vid tidig reumatoid artrit: Hejdar leddestruktion och lindrar symtom

Lakartidningen

Volumn 103, Issue 47, 2006, Pages 3704-3709

  Svensson, Björn ^a   Hafström, Ingiäld ^b  

^a Medicinkliniken   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; GLUCOCORTICOID; PREDNISOLONE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; EARLY DIAGNOSIS; EVIDENCE BASED MEDICINE; HUMAN; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHEUMATOID ARTHRITIS;

ANTI-INFLAMMATORY AGENTS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISEASE PROGRESSION; EARLY DIAGNOSIS; EVIDENCE-BASED MEDICINE; GLUCOCORTICOIDS; HUMANS; PREDNISOLONE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS;

EID: 33751562729     PISSN: 00237205     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. Hench PS, Kendall EC, Slocumb CH, Polley HF. The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocortisone: compound E) and of pituitary adrenocorticotrophic hormone on rheumatoid arthritis. Preliminary report. Proc Staff Meet Mayoclin. 1949;24:181-97.
2. Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Bijlsma JW, et al. Updated consensus statement on biological agents, specifically tumour necrosis factor α (TNFα) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis. 2005;64(Suppl 4):2-14.
3. Buttgereit F, Da Silva JA, Boers M, Burmester GR, Cutolo M, Jacobs J. et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regiments: current questions and tentative answers in rheumatology. Ann Rheum Dis. 2002;61:718-22.
4. Joint Committee of the Medical Research Council and Nuffield Foundation. A comparison of prednisolone with aspirin and other analgesics in the treatment of RA. Ann Rheum Dis. 1959;18:173-87.
5. Byron MA, Kirwan JR. Corticosteroids in rheumatoid arthritis: is a trial of their »disease modifying« potential feasible? Ann Rheum Dis. 1986;45:171-3.
6. Kirwan JR; the Arthritis and Rheumatism Council low-dose glucocorticoid study group. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. N Engl J Med. 1995;333:142-6.
7. Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn. 1977;18:481-91.
8. Boers M, Verhoeven AC, Markusse HM, van der Laar MAF, Westhovens R, van Denderen JC, et al. Randomised comparison of combined step-down prednisolone, metotrexat and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet. 1997;350:309-18.
9. van Everdingen AA, Jacobs JW, Siewertsz van Reesema DR, Bijlsma JW. Low-dose prednisone therapy for patients with early active rheumatoid arthritis; clinical efficacy, disease-modifying properties and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med. 2002;136:1-12.
10. van der Heijde D, van Leeuwen M, van Riel P, Koster AM, van't Hof MA, van Rijswijk MH, et al. Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis. Arthritis Rheum. 1992;35:26-34.
11. Wassenberg S, Rau R, Steinfeld, Zeidler H; for the Low-dose prednisolone therapy study group. Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years. Arthritis Rheum. 2005;52:3371-80.
12. Capell HA, Madhok R, Hunter JA, Porter D, Morrison E, Larkin J, et al. Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial. Ann Rheum Dis. 2004;63:797-803.
13. Kirwan J, Boers M. Low dose prednisolone for treatment of RA. Ann Rheum Dis. 2004;63:1533-4.
14. Svensson B, Boonen A, Albertsson K, van der Heijde D, Keller C, Hafström I; for the BARFOT study group. Low dose prednisolone in addition to the initial DMARD in patients with early active rheumatoid arthritis reduces joint destruction and increases remission rate: a 2-year randomised trial. Arthritis Rheum. 2005;52:3360-70.
15. Gotzsche PC, Johansen HK. Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis. Cochrane Database Syst Rev. 2004;(3):CD000189.
16. Prevoo MLL, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LBA, van Riel PLCM. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44-8.
17. Ekdahl C, Eberhardt K, Andersson SI, Svensson B. Assessing disability in patients with rheumatoid arthritis. Use of a Swedish version of the Stanford health assessment questionnaire. Scand J Rheumatol. 1988;17:263-71.
18. da Silva JA, Jacobs JW, Kirwan JR, Boers M, Saag KG, Ines LB, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis. 2006;65(3):285-93.
19. Verhoeven AC, Boers M. Limited bone loss due to corticosteroids: a systematic review of prospective studies in rheumatoid arthritis and other diseases. J Rheumatol. 1997;24:1495-503.
20. Recommendations for the prevention and treatment of glucocorticoid- induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Arthritis Rheum. 2001;44:1496-503.